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Given the limitations of pegylated interferon (IFN) 
and ribavirin (RBV) therapy for chronic hepatitis C 
virus (HCV) infection, new antiviral medication and 
treatment approaches are sought. Specifically targeted 
antiviral therapies for hepatitis C (STAT-C) refers to 
the use of these new inhibitors, either in combina-
tion with IFN and RBV or other STAT-C agents, to 
improve therapy for HCV. Although many classes 
of inhibitors are being developed, NS3 protease and 
NS5B polymerase inhibitors are likely to be among 
the first STAT-C agents approved. The preclinical and 
clinical characteristics of HCV protease and poly-
merase inhibitors are reviewed in this article. Strengths 
and weaknesses of each class in the context of devel-
oping future all–STAT-C regimens are explored, with 
a particular focus on viral resistance and the prospects 
for eliminating IFN and/or RBV.
Introduction
Therapy for chronic hepatitis C virus (HCV) infection 
saw incremental improvements over the past decade with 
the introduction of pegylated interferons (PEG-IFN), 
weight-based ribavirin (RBV), virologic stopping criteria, 
and improved management of side effects. Despite these 
advances, the rate of sustained virologic response (SVR) 
for genotype 1 HCV following PEG-IFN/RBV therapy 
is about 45% [1]. Gains from further dose and duration 
modification of IFN-based therapy are likely minimal and 
fail to address the large number of patients for whom IFN-
based therapy is contraindicated [2]. Additionally, several 
difficult-to-treat populations (eg, African Americans and 
HIV-1–coinfected individuals) respond significantly less 
well to IFN-based therapy [3,4].
The shortcomings of IFN-based therapy and a sig-
nificant drug discovery effort focusing on HCV resulted 
in an array of virus-specific inhibitors at various stages 
of development. Specifically targeted antiviral therapy 
for hepatitis C (STAT-C) refers to the use of compounds 
targeting HCV proteins or, in some cases, required cel-
lular cofactors to treat persons with hepatitis C. Although 
initial approaches focus on the addition of STAT-C agents 
to PEG-IFN/RBV, the ultimate goal is a potent, well-
tolerated regimen of multiple STAT-C drugs that can be 
administered to an expanded population, including those 
with contraindications to IFN-based therapy. Before 
this goal can be realized, several hurdles must be over-
come, including the vast genetic diversity of HCV, rapid 
development of drug resistance, and drug interactions in 
populations (eg, HIV-1–coinfected persons receiving anti-
retrovirals). In this article, the feasibility and potential of 
STAT-C combination therapy are examined; major classes 
of inhibitors are addressed for their potential in future 
STAT-C combination therapy; and approaches to testing 
and implementing these regimens are discussed.
Hepatitis C Virology: Implications for  
Use of STAT-C Agents
HCV is a positive-sense RNA virus of about 9600 nucleo-
tides encoding a single polyprotein, which is then cleaved 
by host and virally encoded proteases to form functional 
viral proteins. HCV replication occurs in the cytoplasm 
within replication complexes that contain viral and cel-
lular proteins. The viral NS5B RNA–dependent RNA 
polymerase has no proofreading mechanism, resulting in 
a swarm of closely related viral genomes (referred to as a 
quasispecies) within an infected person. As a result of this 
error-prone replication, HCV shows remarkable genetic 
diversity on a population level, with about 35% difference 
in nucleotide sequence between viral genotypes and up 
to 25% difference in subtypes [5]. This genetic diversity 
presents a challenge to the development and implementa-
tion of STAT-C agents. 
Although the error-prone polymerase is a large factor 
in the development of resistance to STAT-C agents, other 
characteristics of the HCV life cycle further compound 
these issues. The amount of virus produced in an infected 
individual is estimated to be 1011 to 1012 virions per day; 
about 10- to 100-fold higher than that seen in HIV-1 
[6•]. The more viral turnover that occurs, the higher 
the likelihood that preexisting resistance mutations will 
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quickly grow out under selective pressure. The HCV 
genome encodes a single polyprotein and does not have 
overlapping reading frames, relaxing the constraints on 
tolerated mutations compared with other chronic viral 
infections (eg, hepatitis B virus [HBV] and to a lesser 
extent HIV-1), which have overlapping reading frames. 
Finally, the life span of infected hepatocytes is shorter 
for HCV than HBV, with an estimated half-life of days 
to several months for HCV and months to years for HBV 
[6•]. In contrast, productively HIV-1–infected CD4 T 
cells have a half-life of about 1 day with rapid turnover, 
creating a large “replication space” for HIV when com-
pared with HCV and HBV. One important difference 
between HCV and both HBV and HIV-1 is the lack of 
an integrated (HIV-1 proviral DNA) or latent (HBV 
cccDNA) cellular form that is capable of archiving resis-
tance mutations and reestablishing active infection after 
antiviral therapy. This characteristic of HCV replication 
may increase the chances of successful STAT-C combina-
tion therapy; however, the impact of potential sanctuary 
sites (eg, the central nervous system) and prolonged 
persistence of relatively fit resistant mutants remains to 
be determined. In sum, these HCV viral characteristics 
suggest that resistance mutations will preexist and be 
selected rapidly during STAT-C antiviral therapy.
Protease Inhibitors 
Overview
The HCV NS3 protease is essential for viral replication; 
by cleaving the single viral polyprotein at several sites, 
the protease creates functional viral proteins. Early rec-
ognition of this role in viral replication and the success 
of similar approaches in HIV-1 therapy led to an intense 
drug-discovery effort targeted at this protein [7]. How-
ever, structural characteristics of the protein proved 
challenging when specific and potent NS3 protease inhibi-
tors (PI) were sought. The protease active site is shallow, 
relatively featureless, and exposed—characteristics that 
make the rational design of inhibitors difficult. Early suc-
cesses focused on modeling candidate inhibitors after the 
authentic viral target and inhibitory cleavage products [8]. 
Following these design paradigms, two structural classes 
of NS3 PIs emerged: macrocyclic compounds and pepti-
domimetic ketoamides. The first proof-of-concept study 
in humans was conducted with BILN-2061 (a macrocy-
clic), and demonstrated the rapid and profound impact 
of PIs on HCV viral load [9]. Subsequent human trials 
confirmed these findings for macrocyclic and ketoamide 
PIs and provided additional insights. The major concepts 
regarding PI-based inhibition of HCV replication are dis-
cussed below and summarized in Table 1.
Illustrative compounds
Several HCV PIs representing different chemical classes 
are at various stages in clinical trials. This review focuses 
on the compounds furthest along in clinical development 
and on those at earlier stages that appear to have unique 
and potentially advantageous characteristics pertaining 
to use in future STAT-C regimens. Two ketoamide HCV 
PIs—telaprevir and boceprevir—have commenced phase 3 
trials after encouraging results in phase 2 trials in combina-
tion with PEG-IFN/RBV. The recently published Protease 
Inhibition for Viral Evaluation (PROVE)-1 and PROVE-2 
studies (ClinicalTrials.gov numbers NCT00372385 and 
NCT00336479, respectively) demonstrated significant 
increases in SVR rates with 12 weeks of telaprevir, 750 
mg three times daily, in combination with 24 weeks of 
PEG-IFN/RBV, compared with controls treated with 
PEG-IFN/RBV for 48 weeks (61% vs 41%, P = 0.02 and 
69% vs 46%, P = 0.004 respectively) [10••,11]. Discon-
tinuations because of adverse events, particularly rash, 
were higher in subjects treated with telaprevir compared 
with controls in the PROVE-1 (21% vs 11%) and PROVE-
2 studies (12% vs 7%). The Serine Protease Inhibitor 
Therapy-1 (SPRINT-1) study (ClinicalTrials.gov number 
NCT00705432) assessed boceprevir, 800 mg three times 
daily, in combination with PEG-IFN/RBV for 28 or 48 
weeks (boceprevir was administered for the entire time); 
SVR rates were 54% and 67% for the durations of 28 
and 48 weeks (38% control, P = 0.013 and P < 0.0001, 
respectively) and 75% with a 4-week lead-in phase with 
PEG-IFN/RBV followed by 44 weeks of PEG-IFN/RBV/
boceprevir [12]. Treatment discontinuations because of 
Table 1. Key concepts for hepatitis C NS3 protease inhibitors
Profound, rapid inhibition of HCV replication
> 3 log by day 3 of therapy for most PIs
Adequate drug exposure is key to maximizing activity and limiting resistance
Exposure prioritized over dosing convenience at this stage of development
Rapid selection and outgrowth of resistant variants occurs during monotherapy
Significant inter- and intragenotype variability exists in the activity and resistance barrier of current clinical lead PIs
Cross-resistance and persistence of resistant mutants may limit sequential treatment options
Mutations R155K and A156T/V confer broad PI cross-resistance
Select resistant mutants can remain significant components of the viral quasispecies for years after exposure 
HCV—hepatitis C virus; PI—protease inhibitor.
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adverse events were higher in the boceprevir arms (11% in 
the 24-week arm and 19% in the 48-week arm) compared 
with controls (8%). 
Differences in trial design and patient populations stud-
ied preclude direct comparison of SVR rates between the 
trials; however, it appears that telaprevir and boceprevir 
comparably and significantly increase SVR rates in naïve 
HCV genotype 1–infected persons, albeit with increased 
rates of adverse events. Differences between the compounds 
focus on adverse effects and potential drug interactions 
because of different metabolic pathways. Tolerability in 
clinical practice may be an issue for both compounds, espe-
cially when coadministered with PEG-IFN/RBV.
The macrocyclic PI BILN-2061 validated the NS3 
protease as an antiviral target, and several macrocyclic 
PIs are currently in clinical trials [13–15]. In early mono-
therapy and IFN combination studies, these inhibitors 
were potent and well tolerated, with the potential for 
once-daily dosing [15]. Finally, compared with other mac-
rocyclic inhibitors, EA-063, a recently described PI, has 
smaller increases in median effective concentration (EC50) 
with several common PI mutations (R155K and D168V) 
in vitro. The significance of this finding in vivo—par-
ticularly in patients who failed other HCV PI therapy—is 
unknown, given that these mutations still result in a 10- to 
500-fold increase in EC50 in vitro to EA-063 [16]. These 
characteristics may offer a higher barrier to resistance 
rather than activity against established mutants.
Resistance to protease inhibitors
Resistance to HCV NS3 PIs is rapidly selected both in vitro 
and in patients during monotherapy—or, importantly, in 
combination with IFN when RBV is omitted or is used at 
low doses [10••,12,17,18,19•]. Substitution of the alanine 
at position 156 with serine (A156S) and the aspartic acid at 
position 168 with valine (D168V) initially were described 
in vitro to confer resistance to ketoamide and macrocyclic 
inhibitors, respectively [17]. It was further shown that sub-
stitutions of valine or threonine at position 156 (A156T/V) 
conferred cross-resistance to ketoamide and macrocyclic 
inhibitors [18]. In vivo, the major HCV PI resistance muta-
tions identified during telaprevir therapy were at serine 156 
(A156S>A156T/V), arginine 155 (R155K/T), threonine 
54 (T54A), and valine 36 (V36M/A) [19•]. The R155K 
mutation has emerged frequently in published trials of PI 
therapy. In vitro, this mutation confers low-level resistance 
(~ 10×) to ketoamide inhibitors and high-level resistance 
to macrocyclic inhibitors (> 100×) while maintaining rep-
licative fitness [20]. Based on in vitro and in vivo studies, 
the R155K mutation confers cross-resistance to all PIs cur-
rently in clinical trials and is fit enough that it occasionally 
was found as a majority species in chronically infected 
persons before PI exposure [21,22•]. In the PROVE-1 and 
2 studies, the R155K mutation (either alone or in combi-
nation with V36M) was the most frequent mutation seen 
in genotype 1a patients with viral breakthrough or relapse 
after therapy; in genotype 1b, mutations at position 156 
tend to be more common because changes at two nucleo-
tides are required for the R155K mutation [10••,11]. 
Mutations at position 36 confer low-level resistance in iso-
lation; however, the significance of this mutation is that, 
when combined with mutations at either the 155 or 156 
position, high-level resistance is observed with improved 
replication fitness [19•]. Long-term follow-up data are still 
being collected, but the R155K, T54A, and V36M muta-
tions persisted for many months to years after the cessation 
of PI therapy in humans [19•,23].
Pretreatment with PEG-IFN/RBV for several weeks 
appears to decrease the rate of breakthrough and resis-
tance development to PIs in early trials [12]. With lower 
replication levels, the ability of the virus to generate 
mutants is decreased and the outgrowth of preexisting 
mutants is hampered. PEG-IFN/RBV lead-in therapy may 
preemptively “pick off” preexisting resistant mutants 
that are less fit for replication in vivo. Poor or null 
responders to IFN-based therapy would not be expected 
to benefit from this approach. This approach is possible 
with PEG-IFN/RBV because of a lack of treatment-spe-
cific resistance mutations. In the future, trials composed 
solely of direct-acting STAT-C agents will require simul-
taneous combination therapy with inhibitors of several 
targets, and/or unique resistance mutations, to present 
a high combined-resistance barrier, as is the norm for 
tuberculosis or HIV-1 therapy.
Potential role of protease inhibitors in STAT-C regimens
Given that PIs are farthest along in development, combined 
with their potency in vivo, they likely will be a prominent 
component of future STAT-C regimens, particularly for 
patients infected with genotype-1 HCV. Additionally, 
high levels (> 20% of the viral quasispecies) of preexist-
ing resistant mutants appear to be relatively rare (1%–5% 
of individuals with genotype 1) [21,22•]. Viral resistance 
may be an issue for patients failing an initial PI-based 
therapy because of cross-resistance conferred by muta-
tions at positions 155 and 156 and prolonged survival of 
resistant mutants after exposure.
Polymerase Inhibitors
Overview
The HCV NS5B RNA–dependent RNA polymerase is 
essential for HCV replication, generating copies of both 
the minus and plus strands of viral RNA during repli-
cation. Crystal structures of the polymerase revealed a 
classic, right-hand configuration RNA polymerase with a 
highly conserved active site and nucleotide triphosphate 
binding tunnel [24]. Additional features of the polymerase 
with implications for STAT-C therapy include the lack of 
a proofreading mechanism (resulting in a high error rate), 
conformation change in the transition from initiation to 
a processive form, requirement of cellular cofactors for 
efficient replication (eg, cyclophilins), and the existence of 
multiple allosteric inhibitor binding sites distinct from the 
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polymerase active site [6•,25,26]. Because of the existence 
of the polymerase active site and multiple allosteric sites, 
two major classes of HCV inhibitors are directed at the 
NS5B polymerase: nucleoside polymerase inhibitors (NIs) 
and nonnucleoside polymerase inhibitors (NNIs). General 
characteristics of polymerase inhibitors as STAT-C agents 
are detailed below and summarized in Table 2.
Nucleoside polymerase inhibitors
NIs target the NS5B polymerase active site by competitively 
inhibiting the incorporation of endogenous nucleotide 
triphosphates in the elongating RNA chain. They func-
tion as chain terminators once incorporated into the RNA 
molecule; however, because most compounds in this class 
possess a 3′OH, they are termed nonobligate chain termi-
nators [27]. NIs are attractive HCV inhibitors for several 
reasons, including the highly conserved nature of the poly-
merase active site, the proven utility of this class of inhibitors 
in other viral disease, and the high barrier to resistance 
described in vitro and in early clinical trials [24,28].
Nonnucleoside polymerase inhibitors
NNIs of the HCV polymerase bind to sites unique from 
the polymerase active site and inhibit its function in a 
noncompetitive manner with nucleotide triphosphates. At 
least four NNI binding sites with multiple chemical classes 
of compounds have been described to inhibit the purified 
polymerase and HCV replication in vitro [26]. Although 
specific mechanisms of action are not defined for all 
NNIs, many appear to exert their effect by inhibiting the 
conformational change necessary for the polymerase to 
go from initiation to elongation [29,30].
Illustrative compounds
The first HCV nucleoside inhibitors described in vitro 
and tested in humans were the 2′-methyl nucleosides, 
with the prototypical compound being a prodrug of 2′C-
methylcytidine [27,31]. Although initial clinical studies 
clearly demonstrated inhibition of HCV replication, early 
compounds were hampered by lack of potency and poor 
tolerability [31]. Second-generation NIs (eg, the 4′azido 
compounds) had improved potency in vivo (2–3 log 
decreases in HCV RNA during monotherapy), but were 
still plagued by poor tolerability, which limited exposure 
and increased relapse rates [32]. Recently, 2′-deoxy HCV 
nucleosides were described, and a related compound R7128 
(a prodrug of 2′-deoxy-2′-fluoro-2′-C-methylcytidine) initi-
ated phase 2b trials in combination with PEG-IFN/RBV 
[33]. During a phase 1b study of R7128, 1500 mg orally, 
twice daily, in combination with PEG-IFN/RBV for 4 
weeks, 85% of subjects had an undetectable HCV viral 
load by the end of administration [34].
Several HCV NNIs were examined in human trials 
with limited success because of lack of efficacy and toler-
ability. Agents currently in clinical trials include ANA-598 
(a palm site inhibitor) and VCH-916 (a thiophene 2-carbox-
ylic acid derivative thumb site inhibitor) [35,36].
Resistance to polymerase inhibitors
Resistance development to NI and NNI polymerase inhibi-
tors is quite different, with NI resistance difficult to select 
in vitro and not yet seen in clinical trials. In contrast, NNI 
resistance is readily selected for both in vitro and in vivo. In 
vitro, the S282T mutation confers modest resistance (two- 
to threefold) to 2′-methyl substitutes nucleosides while 
significantly hampering the replicative fitness of replicons 
(5%–10% of wild-type) [28]. The S96T ± N142T mutations 
confer resistance to the NI 4′-azidocytidine in vitro, again 
with modest changes in EC50 and a dramatic loss in replica-
tive fitness (5%) [28]. These features imply why these sites 
are highly conserved across all HCV genotypes and why 
mutants do not preexist in HCV-infected patients to any 
significant degree [37•]. Nucleoside polymerase inhibitors 
(eg, the recently described 2′-deoxy-4′-azido nucleoside 
analogs) are active in vitro against the S282T and N96T 
mutants, with resistance mutations specific to this com-
pound not reported [33].
Resistance to NNIs at all binding sites was described, 
and the allosteric sites can be identified by their signa-
ture resistance mutations [26]. Resistance to NNIs was 
reviewed [38]. Important features for their utility in STAT-
C regimens include a low genetic barrier to resistance, 
the ability of certain mutations to confer cross-resistance 
to other allosteric sites (eg, C316Y confers resistance 
Table 2. Key concepts for hepatitis C NS5B polymerase inhibitors
Nucleoside inhibitors Nonnucleoside inhibitors
Potent activity with recent nucleosides Modest activity, multiple targets
2–3 log RNA reduction with monotherapy 1–2 log RNA reduction with monotherapy
Broad cross-genotype activity Limited cross-genotype activity
Highly conserved polymerase active site Variability in binding sites
High barrier to resistance Low barrier to resistance
Mutants with low replicative fitness in vitro Mutants relatively fit in vitro
Resistance not yet demonstrated in vivo Rapid resistance in vivo
Preexisting resistance not noted Preexisting resistance prevalent
Potential interaction with ribavirin if coadministered Inhibitors from many chemical classes
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to inhibitors of both palm domains), and preexisting 
resistant mutants within the viral quasispecies in a high 
percentage of naïve patients [37•]. Furthermore, resistant 
variants retain much of their replication fitness in many 
instances, and dual resistance to a combination of a palm 
and thumb inhibitor can be readily selected in vitro [39].
Potential role of polymerase inhibitors  
in STAT-C regimens
NIs are particularly attractive as a component of an 
all–STAT-C regimen because of their high resistance bar-
rier, broad genotype activity, and the low fitness/lack of 
preexistence of polymerase active site mutants. Although 
early trials validated the target, a lack of potency and side 
effects precluded the use of these early agents in STAT-C 
therapy. Current NIs are more potent; however, tolerabil-
ity over 12 to 24 weeks of administration is unproven. 
One complicating factor for NIs, should RBV remain an 
essential component of HCV therapy, is the potential for 
intracellular phosphorylation interactions between RBV 
and nucleoside analogs [40]. 
The large number of allosteric binding sites and the 
diversity of chemical classes from which NNI inhibitors can 
be found increase the likelihood that viable anti-HCV drugs 
may emerge. However, issues such as limited and highly vari-
able activity across and within genotypes may significantly 
limit the number of patients for which any given NNI may 
be useful. Pretherapy resistance testing (sequencing) may be 
necessary to successfully implement NNI therapy in a given 
patient, a scenario that is likely unnecessary for NIs or PIs. 
STAT-C Agents Directed at Other Viral Targets
Inhibitors of several other HCV proteins including 
NS4A, the NS3 helicase, the HCV internal ribosome 
entry site, and NS5A are in various stages of develop-
ment. Although they are not discussed here, the existence 
of multiple targets with multiple inhibitors increases 
the likelihood of realizing potent all–STAT-C regimens 
in the future. Targeting cellular proteins essential for 
HCV replication offers another means of inhibiting HCV 
replication. Current leading examples of such inhibi-
tors include nitazoxanide and cyclophilin inhibitors. 
Nitazoxanide acts through increasing phosphorylation of 
double-stranded RNA–dependent protein kinase (PKR), 
ultimately inhibiting viral translation; nitazoxanide 
inhibits HCV replication in vitro and appears to augment 
the IFN response when coadministered [41]. Similar to 
IFN, no resistance mutations were found in HCV repli-
cons during prolonged exposure. Preliminary results were 
reported in genotype 1 patients treated with combina-
tion therapy including nitazoxanide [42]. Nitazoxanide’s 
clinical safety record (administered as an antiprotozoal 
for prolonged periods in humans) combined with a lack 
of described resistance make it a potential addition 
to STAT-C combination therapy, especially if it has an 
immune-modulating effect in vivo [41]. 
Cyclophilins are abundant host cellular proteins that 
interact with the HCV RNA polymerase and are neces-
sary for efficient HCV replication [25]. Debio 025 is a 
nonimmunosuppressive cyclophilin inhibitor that Is a 
potent HCV inhibitor in vitro and in vivo (-4.61 log for 
Debio 025, 600 mg, combined with PEG-IFN vs -2.49 log 
for PEG-IFN alone for 4 weeks in genotypes 1 and 4) [43]. 
Resistance to cyclosporine and Debio 025 can be selected 
in vitro; however, mutations are scattered throughout 
NS5B and NS5A, and result in only a modest increase in 
EC50 [44]. No resistance mutations were documented in 
vitro during monotherapy or coadministration with IFN; 
thus, it appears the resistance barrier for cyclophilin inhibi-
tors is high, similar to that described for NIs. Although 
these agents do not specifically target HCV viral proteins, 
they possess properties making them attractive as potential 
components of a STAT-C combination regimen.
Will an All–STAT-C Regimen Work?
Unique aspects of IFN and RBV
The mechanism by which IFN-based therapy results in 
cure of chronic HCV is presumably by stimulating cel-
lular antiviral mechanisms and immunomodulation. IFN 
therapy increases HCV-specific CD4 and CD8 T-cell 
responses, and these responses are associated with suc-
cessful HCV therapy [45,46]. Although it seems clear 
that STAT-C agents can replace and even improve on the 
antiviral activity of IFN, whether the immunomodulatory 
effects are critical in achieving SVRs is unknown. HCV 
itself is immunosuppressive, both by direct interference 
with key cellular immune-response pathways (eg, NS3 
protease cleavage of IFN-β promoter stimulator-1) [47] 
and through a more nonspecific “immune exhaustion” 
associated with upregulation of the inhibitory molecule 
programmed death-1 [48]. Use of STAT-C agents should 
reverse these two forms of immunosuppression, but 
whether direct immune stimulation, as occurs with IFN, 
is needed for a durable cure remains the unanswered ques-
tion while all–STAT-C regimens are pursued. 
RBV also was a key component in preventing resistance 
and/or breakthrough during STAT-C combination therapy 
with IFN. Trials with STAT-C agents and PEG-IFN showed 
dramatic increases in viral breakthrough on therapy (PIs 
and NIs), significant increases in viral resistance to PIs, and 
increased relapse rates (PIs and NIs) when RBV is omitted 
or used at low doses [10••,12,32]. RBV may act as both a 
mutagen and an immunomodulator and augments the sec-
ond-phase of viral clearance, which is believed to correlate 
with infected hepatocyte loss [49]. Although it is now clear 
that RBV is necessary if a single STAT-C agent is combined 
with PEG-IFN, additional studies are needed to determine 
if an additional STAT-C agent can replace RBV.
Future directions
The much publicized INFORM-1 trial (ClinicalTrials.
gov number NCT00801255) was the first to assess 
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combination therapy with two STAT-C inhibitors in 
HCV-infected humans [50]. The NI R7128 (PSI-6130) 
was combined with the PI R7227 (ITMN-191) for 14 
days. A decrease of about 5 log in HCV RNA was seen 
in the three highest-dose groups. No viral rebound was 
seen during therapy, in contrast to PI monotherapy, 
where viral rebound can occur as early as day 3. This 
suggests that the addition of a NI with a high barrier 
to resistance can prevent the emergence of PI-resistant 
HCV in the short term. One caveat to this assertion 
is that at this time, details on clonal analysis of viral 
populations for resistance mutations have not been 
presented. It also remains to be seen if subjects with 
breakthrough or relapse in the PEG-IFN/RBV rollover 
portion of the study will have PI or (less likely) NI 
resistance mutations in their viral quasispecies. Based 
on estimates by Perelson [51] from modeling of HCV 
replication and mutation rates in chronically infected 
humans, it seems unlikely that two STAT-C agents will 
be able to present the virus with a high enough resis-
tance barrier to attain prolonged viral suppression and 
sustained responses. 
Taking cues from the INFORM-1 study, what are 
some of the pressing issues as clinical trials of STAT-C 
combinations more forward? Developing a framework 
whereby novel combinations of STAT-C agents can be 
tested effectively in a timely manner is of utmost impor-
tance. Concepts learned during the testing and evolution 
of HIV-1 antiretroviral therapy must not be forgotten. 
National and international clinical trials networks, in 
close collaboration with the pharmaceutical industry 
and drug regulatory boards, will be necessary to push 
the field forward while maintaining patient safety. 
Because drug resistance is likely to be one of the major 
complications for an all–STAT-C regimen, the prospec-
tive, detailed evaluations of resistant viral variants are 
crucial. However, before theses studies can be accom-
plished, definitions and testing methodologies for the 
detection of resistant mutants need to be standardized. 
The HCV Drug Resistance Advisory Group was estab-
lished to meet this goal.
Conclusions
Curing HCV infection with a STAT-C regimen presents 
formidable challenges because of viral characteristics that 
promote rapid resistance development. However, the large 
number of diverse candidate viral inhibitors and success-
ful proof-of-concept clinical studies suggest that such a 
regimen is attainable. Unanswered questions surround the 
need for IFN and/or RBV as adjuncts to STAT-C agents, 
and the number of agents required to prevent resistance 
and viral breakthrough. Although nuances exist in the 
development and implementation of STAT-C combination 
therapy, many concepts fundamental to treating chronic 
viral infections such as HIV-1 undoubtedly apply.
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